[1]黄　洁,陈　实,石　奕,等.拉帕替尼对 A549人肺癌细胞增殖抑制和凋亡机制的实验研究[J].现代检验医学杂志,2022,37(01):154-158.[doi:10.3969/j.issn.1671-7414.2022.01.031]
　HUANG Jie,CHEN Shi,SHI Yi,et al.Experimental Study of Lapatinib on Proliferation Inhibition and Apoptosis of A549 Human Lung Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(01):154-158.[doi:10.3969/j.issn.1671-7414.2022.01.031]
点击复制

拉帕替尼对 A549人肺癌细胞增殖抑制和凋亡机制的实验研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年01期
页码:
154-158
栏目:
论　著
出版日期:
2022-01-15

文章信息/Info

Title:
Experimental Study of Lapatinib on Proliferation Inhibition and Apoptosis of A549 Human Lung Cancer Cells
文章编号:
1671-7414（2022）01-154-05
作者:
黄　洁 ; 陈　实; 石　奕; 李承红; 吴娟娟
（江汉大学附属医院/ 武汉市第六医院呼吸内科，武汉 430025）
Author(s):
HUANG Jie;  CHEN Shi;  SHI Yi;  LI Cheng-hong;  WU Juan-juan
（Department of Respiratory Medicine, Wuhan No.6Hospital ,Affiliated Hospital of Jianghan University, Wuhan 430025, China）
关键词:
人类表皮生长因子受体; 拉帕替尼; 肺癌细胞; 增殖; 细胞周期
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.01.031
文献标志码:
A
摘要:
目的　探讨人表皮生长因子（ ErbB）抑制剂拉帕替尼对肺癌细胞 A549凋亡的影响及其作用机理。方法　2， 4，8 μmol/L的拉帕替尼与 A549肺癌细胞共培养 48 h，MTT检测细胞增殖活力，流式细胞实验检测细胞凋亡与细胞周期，免疫印迹法（ western blot）检测细胞中磷脂酰肌醇 3-激酶（ PI3K）/蛋白激酶 B（AKT）信号通路相关蛋白表达。结果　与对照组（ 0.563±0.056）比较， 2，4，8μmol/L的拉帕替尼能显著降低 A549细胞活性（ 0.492±0.050，0.435±0.044，
Abstract:
Objective　To explore effect of human epidermal growth factor recpetor (ErbB) inhibitor Lapatinib on proliferationand cell cycle in A549 cell. Methods　Cell was cultured by 2, 4, 8 μmol/L dose of Lapatinib for 48 h, cell viability wasmeasured by MTT assay. Cell apoptotic rate and cell cycle was detected by flow cytometry. The expression of phosphatidylinositol3 kinase(PI3K) /protein kinase B protein (AKT) related protein was measured by western blot. Results　Compared withthe control group (0.563±0.056), 2,4,8 μmol/L lapatinib significantly reduced the activity of A549 cells (0.492±0.050,0.435±0.044, 0.356±0.025), with statistical significance (t=2.316, 4.402, 8.267，all P < 0.05).Compared with the controlgroup, 2,4,8 μmol/L lapatinib significantly increased the early apoptosis rates(t=-5.387, -17.921, -19.981, all P<0.05) andlate apoptosis rates (t=-16.174, -19.348, -20.767，all P<0.05) of A549 lung cancer cells, made the cell cycle arrested in G1phase(t=-4.535, -7.276, -9.831, all P<0.05), the differences were statistically significant, repectively. Down-regulated theexpression of CyclinD1(t=2.449, 16.634, 20.208, all P<0.05) and PI3K(t=2.165, 5.388, 17.822, all P<0.05), down-regulatedthe expression of p21(t=2.165, 4.898, 18.416，all P<0.05). 4, 8 μmol/L dose of lapatinib down-regulated the expression ofp-AKT(t=2.486, 18.014，all P<0.05). Conclusion　Lapatinib could induce A549 cell apoptosis and made the cell cycle arrestedin G1 phase by blocking PI3K/Akt signaling pathway.

参考文献/References:

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimatesof incidence and mortality worldwide for 36 cancers in185 countries[J]. CA-A Cancer Journal for Clinicians,2018, 68(6): 394-424.
[2] 赵格, 高琼, 余宗涛, 等．肺癌患者血浆miR-3151表达水平与临床病理特征的相关性研究[J]．现代检验医学杂志, 2020, 35(5): 28-32.ZHAO Ge,GAO Qiong,YU Zongtao, et al. Study onthe correlation between the expression of miR-3151in plasma and clinicopathological features in patientswith lung cancer [J]. Journal of Modern LaboratoryMedicine, 2020, 35(5): 28-32.
[3] 丁贤彬, 唐文革, 曾永胜, 等．2010~2017 年重庆市肺癌发病和死亡趋势变化[J]. 中国肿瘤, 2019,28(8):577-582．DING Xianbin, TANG Wenge, ZENG Yongsheng, et al.Trend of the incidence and mortality of lung cancer inChongqing municipality from 2010 to 2017 [J]. ChinaCancer, 2019, 28(8): 577-582.
[4] WEE P, WANG Zhixiang. Epidermal growth factorreceptor cell proliferation signaling pathways[J].Cancers（Basel）, 2017, 9(5): 52.
[5] 黄芳玲, 彭争荣, 陈主初, 等．ErbB 家族蛋白与肿瘤放射敏感性的研究进展[J]. 中国医师杂志, 2020,22（12）：1917-1920, F3．HUANG Fangling, PENG Zhengrong, CHEN Zhuchu,et al. Study on the relationship between ErbB familyproteins and tumor radiosensitivity [J]. Journal ofChinese Physician, 2020, 22(12): 1917-1920, F3.
[6] 杨超. 人类表皮生长因子受体2 抑制剂在膀胱癌靶向治疗中的研究进展 [J]. 国际泌尿系统杂志, 2020,40(6) : 1123-1126.YANG Chao. Research progress of HER2 inhibitorsin targeted therapy of bladder cancer [J]. InternationalJournal of Urology and Nephrology, 2020, 40(6): 1123-1126.
[7] 张锦锦. 表皮生长因子受体在肿瘤发生、发展中的研究进展[J]．中国生物制品学杂志, 2018, 31（4）：425-430．ZHANG Jinjin. Progress in research on role ofepidermal growth factor receptor in tumorigenesis andtumor development [J]. Chinese Journal of Biologicals,2018, 31(4)：425-430.
[8] 汪霖. 人类表皮生长因子受体2 阳性肿瘤靶向药物研究进展[J]. 实用肿瘤学杂志, 2016, 30(3):266-270.WANG Lin. Research progress on targeted drugs ofhuman epidermal growth factor receptor 2 positivetumours [J].Practical Oncology Journal, 2016, 30(3):266-270.
[9] 王生淋, 余凤强, 林建华．表皮生长因子受体家族在骨肉瘤中的研究进展[J]. 中华实验外科杂志,2018, 35（4）：793-798．WANG Shenglin, YU Fengqiang, LIN Jianhua. Therole of epidermal growth factor receptor family inosteosarcoma [J]. Chinese Journal of ExperimentalSurgery, 2018, 35(4): 793-798.
[10] 杨伟斌, 刘志毅, 曹宽, 等．表皮生长因子受体家族特点及与肿瘤关系的研究进展[J]. 现代肿瘤医学,2019, 27（2）：346-351．YANG Weibin, LIU Zhiyi, CAO Kuan, et al. Researchprogress on the characteristics of epidermal growthfactor receptor family and its relationship with tumors[J]. Journal of Modern Oncology, 2019, 27(2): 346-351.
[11] 柳韵, 冯继锋, 焉兆玥．表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的耐药机制[J]. 国际肿瘤学杂志, 2015, 42（3）：206-209．LIU Yun, FENG Jifeng, YAN Zhaoyue. Researchprogression on resistance mechanisms of epidermalgrowth factor receptor tyrosine kinase ;inhibitors innon-small cell lung cancer [J]. Journal of InternationalOncology, 2015, 42(3): 206-209.
[12] 黄文发, 严颖, 张如艳, 等．曲妥珠单抗和拉帕替尼在辅助曲妥珠单抗治疗后一线复发的HER2 阳性晚期乳腺癌治疗中疗效的比较[J]．肿瘤, 2020,40(9)：641-649．HUANG Wenfa, YAN Ying, ZHANG Ruyan, et al.Efficacy comparison of first-line trastuzumab andlapatinib in HER2-positive advanced breast cancerrelapsed from prior adjuvant trastuzumab treatment[J].Tumor, 2020, 40(9): 641-649.
[13] 徐婷, 陈鹏, 郭丹, 等．依维莫司协同拉帕替尼降低HER2+ 乳腺癌对拉帕替尼耐药[J]. 基因组学与应用生物学, 2020, 39(5): 2411-2417.XU Ting,CHEN Peng,GUO Dan,et al. Everolimussynergize with lapatinib reduced the resistance ofHER2+ breast cancer to lapatinib[J]. Genomics andApplied Biology, 2020, 39(5): 2411-2417.
[14] 陈鹏, 徐婷, 郭丹, 等．YAP 蛋白在HER2 阳性乳腺癌拉帕替尼耐药中的作用[J]．第三军医大学学报,2020, 42(7)：692-698．CHEN Peng, XU Ting, GUO Dan, et al. Role of yesassociatedprotein in resistance of HER2+ breast cancerto lapatinib [J]. Journal of Third Military MedicalUniversity, 2020, 42(7): 693-698.
[15] 陈涛, 李雄伟, 孙晓东．拉帕替尼和紫杉醇在食管癌细胞中的抗肿瘤活性及其作用机制[J]. 肿瘤防治研究, 2021, 48(1):19-23.CHEN Tao, LI Xiongwei, SUN Xiaodong. Synergisticantitumor activity and mechanism of lapatinib andpaclitaxel in esophageal cancer cells [J]. CancerResearch on Prevention and Treatment, 2021, 48(1):19-23.
[16] LEE H J, SHIN S, KANG J, et al. HSP90 inhibitor,17-DMAG, alone and in combination with lapatinibattenuates acquired lapatinib-resistance in ER-positive,HER2-overexpressing breast cancer cell line[J].Cancers, 2020, 12(9): 2630.
[17] 豆巧华, 郭晓芳, 朱小飞, 等. 拉帕替尼联合顺铂抗食管鳞癌的作用及机制[J]. 肿瘤防治研究, 2019,46(9):766-772.DOU Qiaohua, GUO Xiaofang, ZHU Xiaofei, et al.Antitumor efficacy and mechanisms of lapatinib incombination with cisplatin on esophageal squamouscancer cells [J]. Cancer Research on Prevention andTreatment, 2019, 46(9): 766-772.
[18] MOURA A C, ASSAD D X, AMORIM DOS SANTOSJ, et al. Worldwide prevalence of PI3K-AKTmTORpathway mutations in head and neck cancer:A systematic review and meta-analysis [J]. CriticalReviews in Oncology Hematology, 2021, 160: 103284.
[19] BARKER R M, HOLLY J M P, BIERNACKA K M,et al. Mini review: Opposing pathologies in cancerand alzheimer’s disease: does the pi3k/akt pathwayprovide clues[J]. Front Endocrinol (Lausanne),2020,11:403.
[20] SHORNING B Y, DASS M S, SMALLEY M J, et al.The PI3K-AKT-mTOR pathway and prostate cancer:atthe crossroads of AR,MAPK,and WNT signaling[J].International Journal of Molecular Sciences, 2020,21(12): 57-62.
[21] 汪蔷华, 庞青, 王学故, 等. 肝癌细胞PI3K/Akt 信号通路在干扰素2α 上调ISG15 表达中的作用[J]. 中华全科医学, 2021, 19(2):182-185, 269.WANG Qianghua, PANG Qing, WANG Xuegu, et al.The role of PI3K/Akt signaling pathway in upregulationof ISG15 induced by interferon 2α in hepatocellularcarcinoma cells [J]. Chinese Journal of GeneralPractice, 2021, 19(2):182-185,269.
[22] 刘路, 刘北忠, 赵毅, 等. 拉帕替尼通过激活P38MAPK 信号通路促进NB4 细胞凋亡[J]. 中国细胞生物学学报，2017，39(11):1390-1396.LIU Lu, LIU Beizhong, ZHAO Yi, et al. Effects of lapatinibon cell proliferation and apoptosis in NB4 cells[J].Chinese Journal of Cell Biology, 2017,39(11):1390-1396.

备注/Memo

备注/Memo:
基金项目：武汉市卫生健康科研项目（WX17C30)。
作者简介：黄洁（1979-），女，硕士，副主任医师，主要从事慢性气道疾病和呼吸介入治疗。
通讯作者：李承红（1969-），女，硕士，主任医师，主要从事慢性气道疾病和呼吸介入治疗，E-mail：15827636399@163.com。
更新日期/Last Update: 1900-01-01